Andrzej Szyszka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrzej Szyszka has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Rafał Dankowski
Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
7 shared publications - Wioletta Sacharczuk
2nd Department of Cardiology, Poznan University of Medical Sciences, Poland
4 shared publications - Artur Baszko
Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
2 shared publications - Andrzej Tomaszewski
Department of Cardiology, Medical University of Lublin , Jaczewskiego 8, 20-090 Lublin
1 shared publication - Anna Kłusek-Zielińska
2nd Department of Cardiology, Poznan University of Medical Sciences , 28 Czerwca 1956 r., no 194, 61-485 Poznan , Poland
1 shared publication - Anna Marciniak
Department of Cardiology, St George’s University Hospitals NHS Foundation Trust , Blackshaw Road, Tooting, London SW17 0QT, UK
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (11) , 1926-1936
Sex-specific patterns of valvulo-aortopathy in bicuspid aortic valve according to the international consensus framework: insights from the RE-BAV registry
Aims: To characterize sex-specific patterns of bicuspid aortic valve (BAV) valvulo-aortopathy using consensus phenotyping and to assess how aortic normalization strategies influence sex-related differences in aortic dimensions. Methods and results: We analysed 808 adults with BAV (mean age 49.9 ± 17.5 years; 588 men) from the RE-BAV registry. Valve morphology, aortopathy phenotypes, and clinical valvulo-aortopathy categories were classified according to consensus definitions. Typical and uncomplicated forms were additionally analysed together as a non-complex category. Proximal aortic dimensions were defined as the aortic root and ascending aorta. Valve morphology distribution did not differ by sex. Although the prevalence of aortic dilatation was similar, phenotype distribution differed: women more frequently exhibited the extended phenotype (34.7% vs. 23.3%, P = 0.001), whereas the root phenotype was more common in men (15.1% vs. 7.8%, P = 0.006). Moderate-to-severe aortic regurgitation was more prevalent in men (50.3% vs. 29.1%, P < 0.001). Sex differences in proximal aortic dimensions varied by normalization strategy. For the ascending aorta, indexing to body surface area yielded larger values in women (21.1 ± 4.0 vs. 20.0 ± 4.0 mm/m², P = 0.001), whereas diameter/height showed no sex-related difference at this level. Conversely, the cross-sectional area-to-height ratio remained higher in men across proximal segments, most prominently at the sinuses of Valsalva (6.9 ± 2.0 vs. 5.6 ± 1.6 cm²/m, P < 0.001). Age was independently associated with larger proximal aortic dimensions across all strategies. Conclusion: Sex-related differences in BAV involved aortopathy phenotype, aortic regurgitation burden, and proximal aortic dimensions. Interpretation of proximal aortic dimensions depended on the normalization strategy used, indicating that indexing methods should not be treated as interchangeable.
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (11) , 1926-1936
Open AccessSex-specific patterns of valvulo-aortopathy in bicuspid aortic valve according to the international consensus framework: insights from the RE-BAV registry
Aims: To characterize sex-specific patterns of bicuspid aortic valve (BAV) valvulo-aortopathy using consensus phenotyping and to assess how aortic normalization strategies influence sex-related differences in aortic dimensions. Methods and results: We analysed 808 adults with BAV (mean age 49.9 ± 17.5 years; 588 men) from the RE-BAV registry. Valve morphology, aortopathy phenotypes, and clinical valvulo-aortopathy categories were classified according to consensus definitions. Typical and uncomplicated forms were additionally analysed together as a non-complex category. Proximal aortic dimensions were defined as the aortic root and ascending aorta. Valve morphology distribution did not differ by sex. Although the prevalence of aortic dilatation was similar, phenotype distribution differed: women more frequently exhibited the extended phenotype (34.7% vs. 23.3%, P = 0.001), whereas the root phenotype was more common in men (15.1% vs. 7.8%, P = 0.006). Moderate-to-severe aortic regurgitation was more prevalent in men (50.3% vs. 29.1%, P < 0.001). Sex differences in proximal aortic dimensions varied by normalization strategy. For the ascending aorta, indexing to body surface area yielded larger values in women (21.1 ± 4.0 vs. 20.0 ± 4.0 mm/m², P = 0.001), whereas diameter/height showed no sex-related difference at this level. Conversely, the cross-sectional area-to-height ratio remained higher in men across proximal segments, most prominently at the sinuses of Valsalva (6.9 ± 2.0 vs. 5.6 ± 1.6 cm²/m, P < 0.001). Age was independently associated with larger proximal aortic dimensions across all strategies. Conclusion: Sex-related differences in BAV involved aortopathy phenotype, aortic regurgitation burden, and proximal aortic dimensions. Interpretation of proximal aortic dimensions depended on the normalization strategy used, indicating that indexing methods should not be treated as interchangeable.
- Open Access
- 23 January 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 25 (7) , e183
Multimodality imaging of a rare complication: interventricular septal haematoma in left bundle branch pacing
A 65-year-old male patient was admitted for pacemaker implantation. The procedure was uneventful, and the left bundle branch pacing system was implanted. Subsequently, 6 h post-procedure, the patient presented with anginal pain. An electrocardiogram revealed ST-segment elevations in the precordial leads. A subsequent echocardiogram showed a significantly thickened interventricular septum with non-homogeneous echogenicity (Panels A and B, Supplementary data online , Video S1). Urgent coronary angiography showed the extravasation of contrast into the myocardium from two small septal arteries, forming an intramyocardial haematoma (Panel C, Supplementary data online , Video S2). As the patient’s status remained stable, conservative treatment was chosen.
- 23 January 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 25 (7) , e183
Open AccessMultimodality imaging of a rare complication: interventricular septal haematoma in left bundle branch pacing
A 65-year-old male patient was admitted for pacemaker implantation. The procedure was uneventful, and the left bundle branch pacing system was implanted. Subsequently, 6 h post-procedure, the patient presented with anginal pain. An electrocardiogram revealed ST-segment elevations in the precordial leads. A subsequent echocardiogram showed a significantly thickened interventricular septum with non-homogeneous echogenicity (Panels A and B, Supplementary data online , Video S1). Urgent coronary angiography showed the extravasation of contrast into the myocardium from two small septal arteries, forming an intramyocardial haematoma (Panel C, Supplementary data online , Video S2). As the patient’s status remained stable, conservative treatment was chosen.
- Open Access
- 31 March 2022
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 91 (1) , e606
First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure
We investigated the early effects of low dose sacubitril/valsartan (S/V) on cardiac reverse remodeling (CRR). Methods: In 37 patients (45- excluded 8pts,mean age 64.5±17.5 years, five females), 24/26 mg S/V BID was started, and the second evaluation was performed after month. Results: Following CRR parameters improved: LVEDD (-∆2,9±2.6 mm; Student’s t-test: p =0.0098), LVESD (-∆2,4±2.5 mm; Student’s t-test: p=0.0092), LVEDV (-∆14.6±33.1 mL; Wilcoxon test: p = 0.0412), LVESV (-∆13.4±30.6 mL; Wilcoxon test: p =0.0442), LAVI (-∆8.7±37.7 mL/m2; Wilcoxon test: p = 0.0012), and EROA (-∆0.09±0.01 cm2; Student’s t-test: p = 0.0318). In opposite to LVEF, global longitudinal strain (GLS) changed from -6.6% to -7.9% (absolute improvement of 16%, Wilcoxon test: p=0.0013). Other parameters improving: 6-MWT (+∆65.4±75.8 m; Wilcoxon test: p = 0.0013) and the quality of life (MLHFQ 22 vs 16 scores; Student’s t-test: p= 0.0098), NT-pro BNP (-∆1203.1±3121.4 pg/mL; Student’s t-test: p = 0.0348) and troponin T (-∆ 4.7±9.4 pg/mL, Wilcoxon test: p = 0.0041). Correlation between GLS and LVESV (Pearson's correlation coefficient: r = -0,4596, p = 0.0239) was found. ROC curve analysis showed that in the group with severe systolic dysfunction (GLS< -8%) clinical improvement (6MWT: AUC = 0.692, p = 0.0383) and CRR (MRvol: AUC = 0.736, p = 0.0062; LAVI: AUC = 0.710, p = 0.0414) are more likely to occur. Conclusions: Low-dose (24/26 mg BID) S/V therapy initiates CRR. S/V should be started in patients with less impaired LV systolic function (GLS < -8%) because CRR and clinical improvement are more likely to develop.
- 31 March 2022
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 91 (1) , e606
Open AccessFirst signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure
We investigated the early effects of low dose sacubitril/valsartan (S/V) on cardiac reverse remodeling (CRR). Methods: In 37 patients (45- excluded 8pts,mean age 64.5±17.5 years, five females), 24/26 mg S/V BID was started, and the second evaluation was performed after month. Results: Following CRR parameters improved: LVEDD (-∆2,9±2.6 mm; Student’s t-test: p =0.0098), LVESD (-∆2,4±2.5 mm; Student’s t-test: p=0.0092), LVEDV (-∆14.6±33.1 mL; Wilcoxon test: p = 0.0412), LVESV (-∆13.4±30.6 mL; Wilcoxon test: p =0.0442), LAVI (-∆8.7±37.7 mL/m2; Wilcoxon test: p = 0.0012), and EROA (-∆0.09±0.01 cm2; Student’s t-test: p = 0.0318). In opposite to LVEF, global longitudinal strain (GLS) changed from -6.6% to -7.9% (absolute improvement of 16%, Wilcoxon test: p=0.0013). Other parameters improving: 6-MWT (+∆65.4±75.8 m; Wilcoxon test: p = 0.0013) and the quality of life (MLHFQ 22 vs 16 scores; Student’s t-test: p= 0.0098), NT-pro BNP (-∆1203.1±3121.4 pg/mL; Student’s t-test: p = 0.0348) and troponin T (-∆ 4.7±9.4 pg/mL, Wilcoxon test: p = 0.0041). Correlation between GLS and LVESV (Pearson's correlation coefficient: r = -0,4596, p = 0.0239) was found. ROC curve analysis showed that in the group with severe systolic dysfunction (GLS< -8%) clinical improvement (6MWT: AUC = 0.692, p = 0.0383) and CRR (MRvol: AUC = 0.736, p = 0.0062; LAVI: AUC = 0.710, p = 0.0414) are more likely to occur. Conclusions: Low-dose (24/26 mg BID) S/V therapy initiates CRR. S/V should be started in patients with less impaired LV systolic function (GLS < -8%) because CRR and clinical improvement are more likely to develop.
- Open Access
- 28 September 2021
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 90 (3) , e532
Cardiovascular imaging in the acute phase of coronavirus disease 2019 (COVID-19)
The coronavirus disease 2019 (COVID-19) has become the most critical healthcare issue worldwide since the pandemic was announced in March 2020. Although respiratory symptoms remain the critical characteristic feature of COVID-19 (with acute respiratory syndrome as the leading cause of mortality), the disease also affects other organs. In fact, the involvement of the cardiovascular system during COVID-19 may include acute coronary symptoms, acute heart failure and myocarditis, arrhythmias, cardiac tamponade, pulmonary embolism, and right ventricular failure due to a high-pressure mechanical ventilation. It is vital to note that all of the abovementioned disorders require specific, pandemic-adapted imaging algorithms. This brief review aims to discuss different cardiac imaging modalities to demonstrate their effectiveness in managing patients in the acute phase of COVID-19.
- 28 September 2021
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 90 (3) , e532
Open AccessCardiovascular imaging in the acute phase of coronavirus disease 2019 (COVID-19)
The coronavirus disease 2019 (COVID-19) has become the most critical healthcare issue worldwide since the pandemic was announced in March 2020. Although respiratory symptoms remain the critical characteristic feature of COVID-19 (with acute respiratory syndrome as the leading cause of mortality), the disease also affects other organs. In fact, the involvement of the cardiovascular system during COVID-19 may include acute coronary symptoms, acute heart failure and myocarditis, arrhythmias, cardiac tamponade, pulmonary embolism, and right ventricular failure due to a high-pressure mechanical ventilation. It is vital to note that all of the abovementioned disorders require specific, pandemic-adapted imaging algorithms. This brief review aims to discuss different cardiac imaging modalities to demonstrate their effectiveness in managing patients in the acute phase of COVID-19.
- 6 March 2021
- Published by Wiley in Echocardiography
- Vol. 38 (4) , 686-692
The usefulness of echocardiography in the diagnosis of myocarditis in a young man after sudden cardiac arrest
The diagnosis of acute myocarditis (AM) remains challenging because of its diverse clinical manifestations. Thus, a wide range of diagnostic tests may be warranted. Although cardiac magnetic resonance (CMR) is the preferred imaging technique, it may not be applicable in the acute AM phase. Our case report highlights the usefulness and diagnostic accuracy of echocardiographic examination. In the first 2‐dimensional echocardiography, the focal echobright was presented. A reduced value of global longitudinal strain and regional disturbances of segmental myocardial strain, both longitudinal and circumferential, in the epicardial layer, were detected with a good correlation with CMR results.
- 6 March 2021
- Published by Wiley in Echocardiography
- Vol. 38 (4) , 686-692
The usefulness of echocardiography in the diagnosis of myocarditis in a young man after sudden cardiac arrest
The diagnosis of acute myocarditis (AM) remains challenging because of its diverse clinical manifestations. Thus, a wide range of diagnostic tests may be warranted. Although cardiac magnetic resonance (CMR) is the preferred imaging technique, it may not be applicable in the acute AM phase. Our case report highlights the usefulness and diagnostic accuracy of echocardiographic examination. In the first 2‐dimensional echocardiography, the focal echobright was presented. A reduced value of global longitudinal strain and regional disturbances of segmental myocardial strain, both longitudinal and circumferential, in the epicardial layer, were detected with a good correlation with CMR results.
- 3 April 2019
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 88 (2) , 123-128
A thousand words about the imaging in cardiac amyloidosis
Cardiac amyloidosis is an infiltrative disease which usually occurs under the form of restrictive cardiomyopathy. Advances in the treatment have changed the unfavorable outcomes of this disease. Thus, early diagnosis is essential. Recent advances in echocardiography and cardiac magnetic resonance provided new modalities for the detection of cardiac amyloidosis. This summary discusses the role of imaging techniques in the diagnosis of cardiac amyloidosis.
- 3 April 2019
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 88 (2) , 123-128
A thousand words about the imaging in cardiac amyloidosis
Cardiac amyloidosis is an infiltrative disease which usually occurs under the form of restrictive cardiomyopathy. Advances in the treatment have changed the unfavorable outcomes of this disease. Thus, early diagnosis is essential. Recent advances in echocardiography and cardiac magnetic resonance provided new modalities for the detection of cardiac amyloidosis. This summary discusses the role of imaging techniques in the diagnosis of cardiac amyloidosis.
- Open Access
- 14 April 2017
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 75 (4) , 323-331
Hospitalisation length and prognosis in heart failure patients
Background: Heart failure (HF) is a chronic disease with poor prognosis, being the final stage of many cardiovascular conditions and often requiring hospitalisation. Aim: The aim of the study was to evaluate the effect of hospitalisation length on prognosis in patients with HF. Methods: Between February 2012 and January 2013, in 32 cardiology centres in Poland, 1126 HF patients were included in the EURObservational Research Programme on Heart Failure Registry. A total of 765 persons were hospitalised. A follow-up (FU) of 414 ± 121 days was conducted. Results: The median length of hospitalisation was seven days (interquartiles 25th–75th; 4–11), also for new onset (14.5% of patients) and chronic HF (seven days, 5–11 and 4–11, respectively). Patients who died during FU (16.5%) and those who survived were hospitalised for a median of eight days (6–12) and seven days (4–10), respectively (p < 0.001). Patients hospitalised for 8–21 and 22 or more days had an increased risk of death after discharge (hazard ratio [HR] 1.70; 95% confidence interval [CI] 1.16–2.49 and HR 2.20; 95% CI 1.04–4.67, respectively) than those hospitalised for up to seven days. Predictors of death in the FU period in multivariate analysis included age (1.02; 95% CI 1.01–1.04), history of chronic kidney disease (CKD) (HR 1.55; 95% CI 1.05–2.30), and New York Heart Association (NYHA) class III (HR 2.52; 95% CI 1.22–5.18) and IV (HR 4.77; 95% CI 2.32–9.82) at admission. Patients hospitalised for 22 or more days were more often male (77%), and with a history of CKD (34%). At admission they had lower systolic (118 ± 25 mm Hg) and diastolic (72 ± 12 mm Hg) blood pressure, higher NT-proBNP (9191 ± 8776 pg/mL), lower serum sodium level (137 ± 5 mmol/l), as well as lower ejection fraction before and during hospital stay (30 ± 12% and 34 ± 14%, respectively; p < 0.05 for all factors). Factors that influenced the length of hospital stay included history of CKD (p < 0.001), current malignancy (p = 0.026), and infection at admission (p < 0.001). Most of the admitted patients presented NYHA class III (45%). The poorer the NYHA class at admission, the longer the patient’s hospital stay (p < 0.001). 54% patients were re-admitted to the hospital during FU. Patients re-admitted and not re-admitted during the one-year FU had the same median duration of the index hospitalisation (seven days; 4–10 and 4–11, respectively; p = 0.957). Conclusions: Patients with HF hospitalised for 22 or more days, in comparison to patients hospitalised for less than eight days, had double the risk of death during FU. We believe that prolonged hospitalisation might be regarded as a marker of poor prognosis in patients with acute HF. Background: Heart failure (HF) is a chronic disease with poor prognosis, being the final stage of many cardiovascular conditions and often requiring hospitalisation. Aim: The aim of the study was to evaluate the effect of hospitalisation length on prognosis in patients with HF. Methods: Between February 2012 and January 2013, in 32 cardiology centres in Poland, 1126 HF patients were included in the EURObservational Research Programme on Heart Failure Registry. A total of 765 persons were hospitalised. A follow-up (FU) of 414 ± 121 days was conducted. Results: The median length of hospitalisation was seven days (interquartiles 25th–75th; 4–11), also for new onset (14.5% of patients) and chronic HF (seven days, 5–11 and 4–11, respectively). Patients who died during FU (16.5%) and those who survived were hospitalised for a median of eight days (6–12) and seven days (4–10), respectively (p < 0.001). Patients hospitalised for 8–21 and 22 or more days had an increased risk of death after discharge (hazard ratio [HR] 1.70; 95% confidence interval [CI] 1.16–2.49 and HR 2.20; 95% CI 1.04–4.67, respectively) than those hospitalised for up to seven days. Predictors of death in the FU period in multivariate analysis included age (1.02; 95% CI 1.01–1.04), history of chronic kidney disease (CKD) (HR 1.55; 95% CI 1.05–2.30), and New York Heart Association (NYHA) class III (HR 2.52; 95% CI 1.22–5.18) and IV (HR 4.77; 95% CI 2.32–9.82) at admission. Patients hospitalised for 22 or more days were more often male (77%), and with a history of CKD (34%). At admission they had lower systolic (118 ± 25 mm Hg) and diastolic (72 ± 12 mm Hg) blood pressure, higher NT-proBNP (9191 ± 8776 pg/mL), lower serum sodium level (137 ± 5 mmol/l), as well as lower ejection fraction before and during hospital stay (30 ± 12% and 34 ± 14%, respectively; p < 0.05 for all factors). Factors that influenced the length of hospital stay included history of CKD (p < 0.001), current malignancy (p = 0.026), and infection at admission (p < 0.001). Most of the admitted patients presented NYHA class III (45%). The poorer the NYHA class at admission, the longer the patient’s hospital stay (p < 0.001). 54% patients were re-admitted to the hospital during FU. Patients re-admitted and not re-admitted during the one-year FU had the same median duration of the index hospitalisation (seven days; 4–10 and 4–11, respectively; p = 0.957). Conclusions: Patients with HF hospitalised for 22 or more days, in comparison to patients hospitalised for less than eight days, had double the risk of death during FU. We believe that prolonged hospitalisation might be regarded as a marker of poor prognosis in patients with acute HF.
- 14 April 2017
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 75 (4) , 323-331
Open AccessHospitalisation length and prognosis in heart failure patients
Background: Heart failure (HF) is a chronic disease with poor prognosis, being the final stage of many cardiovascular conditions and often requiring hospitalisation. Aim: The aim of the study was to evaluate the effect of hospitalisation length on prognosis in patients with HF. Methods: Between February 2012 and January 2013, in 32 cardiology centres in Poland, 1126 HF patients were included in the EURObservational Research Programme on Heart Failure Registry. A total of 765 persons were hospitalised. A follow-up (FU) of 414 ± 121 days was conducted. Results: The median length of hospitalisation was seven days (interquartiles 25th–75th; 4–11), also for new onset (14.5% of patients) and chronic HF (seven days, 5–11 and 4–11, respectively). Patients who died during FU (16.5%) and those who survived were hospitalised for a median of eight days (6–12) and seven days (4–10), respectively (p < 0.001). Patients hospitalised for 8–21 and 22 or more days had an increased risk of death after discharge (hazard ratio [HR] 1.70; 95% confidence interval [CI] 1.16–2.49 and HR 2.20; 95% CI 1.04–4.67, respectively) than those hospitalised for up to seven days. Predictors of death in the FU period in multivariate analysis included age (1.02; 95% CI 1.01–1.04), history of chronic kidney disease (CKD) (HR 1.55; 95% CI 1.05–2.30), and New York Heart Association (NYHA) class III (HR 2.52; 95% CI 1.22–5.18) and IV (HR 4.77; 95% CI 2.32–9.82) at admission. Patients hospitalised for 22 or more days were more often male (77%), and with a history of CKD (34%). At admission they had lower systolic (118 ± 25 mm Hg) and diastolic (72 ± 12 mm Hg) blood pressure, higher NT-proBNP (9191 ± 8776 pg/mL), lower serum sodium level (137 ± 5 mmol/l), as well as lower ejection fraction before and during hospital stay (30 ± 12% and 34 ± 14%, respectively; p < 0.05 for all factors). Factors that influenced the length of hospital stay included history of CKD (p < 0.001), current malignancy (p = 0.026), and infection at admission (p < 0.001). Most of the admitted patients presented NYHA class III (45%). The poorer the NYHA class at admission, the longer the patient’s hospital stay (p < 0.001). 54% patients were re-admitted to the hospital during FU. Patients re-admitted and not re-admitted during the one-year FU had the same median duration of the index hospitalisation (seven days; 4–10 and 4–11, respectively; p = 0.957). Conclusions: Patients with HF hospitalised for 22 or more days, in comparison to patients hospitalised for less than eight days, had double the risk of death during FU. We believe that prolonged hospitalisation might be regarded as a marker of poor prognosis in patients with acute HF. Background: Heart failure (HF) is a chronic disease with poor prognosis, being the final stage of many cardiovascular conditions and often requiring hospitalisation. Aim: The aim of the study was to evaluate the effect of hospitalisation length on prognosis in patients with HF. Methods: Between February 2012 and January 2013, in 32 cardiology centres in Poland, 1126 HF patients were included in the EURObservational Research Programme on Heart Failure Registry. A total of 765 persons were hospitalised. A follow-up (FU) of 414 ± 121 days was conducted. Results: The median length of hospitalisation was seven days (interquartiles 25th–75th; 4–11), also for new onset (14.5% of patients) and chronic HF (seven days, 5–11 and 4–11, respectively). Patients who died during FU (16.5%) and those who survived were hospitalised for a median of eight days (6–12) and seven days (4–10), respectively (p < 0.001). Patients hospitalised for 8–21 and 22 or more days had an increased risk of death after discharge (hazard ratio [HR] 1.70; 95% confidence interval [CI] 1.16–2.49 and HR 2.20; 95% CI 1.04–4.67, respectively) than those hospitalised for up to seven days. Predictors of death in the FU period in multivariate analysis included age (1.02; 95% CI 1.01–1.04), history of chronic kidney disease (CKD) (HR 1.55; 95% CI 1.05–2.30), and New York Heart Association (NYHA) class III (HR 2.52; 95% CI 1.22–5.18) and IV (HR 4.77; 95% CI 2.32–9.82) at admission. Patients hospitalised for 22 or more days were more often male (77%), and with a history of CKD (34%). At admission they had lower systolic (118 ± 25 mm Hg) and diastolic (72 ± 12 mm Hg) blood pressure, higher NT-proBNP (9191 ± 8776 pg/mL), lower serum sodium level (137 ± 5 mmol/l), as well as lower ejection fraction before and during hospital stay (30 ± 12% and 34 ± 14%, respectively; p < 0.05 for all factors). Factors that influenced the length of hospital stay included history of CKD (p < 0.001), current malignancy (p = 0.026), and infection at admission (p < 0.001). Most of the admitted patients presented NYHA class III (45%). The poorer the NYHA class at admission, the longer the patient’s hospital stay (p < 0.001). 54% patients were re-admitted to the hospital during FU. Patients re-admitted and not re-admitted during the one-year FU had the same median duration of the index hospitalisation (seven days; 4–10 and 4–11, respectively; p = 0.957). Conclusions: Patients with HF hospitalised for 22 or more days, in comparison to patients hospitalised for less than eight days, had double the risk of death during FU. We believe that prolonged hospitalisation might be regarded as a marker of poor prognosis in patients with acute HF.